FY2018 EPS Estimates for Hologic, Inc. Lowered by Analyst (HOLX)

Hologic, Inc. (NASDAQ:HOLX) – Equities researchers at Leerink Swann reduced their FY2018 earnings estimates for Hologic in a research report issued on Thursday, October 11th. Leerink Swann analyst R. Newitter now expects that the medical equipment provider will earn $2.24 per share for the year, down from their previous estimate of $2.25. Leerink Swann also issued estimates for Hologic’s Q4 2018 earnings at $0.59 EPS, FY2019 earnings at $2.40 EPS and FY2020 earnings at $2.61 EPS.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Tuesday, July 31st. The medical equipment provider reported $0.58 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.02. Hologic had a positive return on equity of 22.18% and a negative net margin of 2.47%. The business had revenue of $824.00 million for the quarter, compared to analysts’ expectations of $800.14 million.

Several other research analysts have also recently weighed in on HOLX. Zacks Investment Research cut Hologic from a “hold” rating to a “sell” rating in a research report on Tuesday, July 3rd. ValuEngine raised Hologic from a “sell” rating to a “hold” rating in a research report on Wednesday, July 11th. BidaskClub raised Hologic from a “hold” rating to a “buy” rating in a research report on Wednesday, August 1st. Needham & Company LLC boosted their price objective on Hologic from $43.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, August 1st. Finally, Deutsche Bank boosted their price objective on Hologic from $42.00 to $45.00 and gave the stock a “hold” rating in a research report on Wednesday, August 1st. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the company’s stock. Hologic presently has an average rating of “Hold” and an average target price of $44.47.

HOLX stock opened at $40.04 on Monday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.29. Hologic has a 1-year low of $35.10 and a 1-year high of $45.09. The firm has a market capitalization of $11.15 billion, a price-to-earnings ratio of 19.72, a price-to-earnings-growth ratio of 2.01 and a beta of 0.67.

In other Hologic news, insider Benjamin Jordan Cohn sold 3,437 shares of the business’s stock in a transaction on Wednesday, September 19th. The stock was sold at an average price of $41.50, for a total value of $142,635.50. Following the sale, the insider now directly owns 16,520 shares in the company, valued at $685,580. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Sally Crawford sold 13,257 shares of the business’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $39.54, for a total value of $524,181.78. Following the completion of the sale, the director now owns 167,701 shares in the company, valued at $6,630,897.54. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,661 shares of company stock worth $1,927,174. Corporate insiders own 0.88% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of HOLX. Stifel Financial Corp raised its stake in shares of Hologic by 75.0% in the first quarter. Stifel Financial Corp now owns 22,594 shares of the medical equipment provider’s stock valued at $847,000 after buying an additional 9,684 shares during the period. Principal Financial Group Inc. raised its stake in shares of Hologic by 0.5% during the 1st quarter. Principal Financial Group Inc. now owns 406,319 shares of the medical equipment provider’s stock valued at $15,180,000 after purchasing an additional 2,131 shares during the period. United Capital Financial Advisers LLC raised its stake in shares of Hologic by 34.4% during the 1st quarter. United Capital Financial Advisers LLC now owns 6,395 shares of the medical equipment provider’s stock valued at $239,000 after purchasing an additional 1,638 shares during the period. Jane Street Group LLC raised its stake in shares of Hologic by 30.3% during the 1st quarter. Jane Street Group LLC now owns 6,904 shares of the medical equipment provider’s stock valued at $258,000 after purchasing an additional 1,607 shares during the period. Finally, Amundi Pioneer Asset Management Inc. raised its stake in shares of Hologic by 818.9% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 1,521,695 shares of the medical equipment provider’s stock valued at $56,851,000 after purchasing an additional 1,356,091 shares during the period. Hedge funds and other institutional investors own 98.65% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Further Reading: Fundamental Analysis – How It Helps Investors

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply